APP
BMY icon

Alpha Paradigm Partners’s Bristol-Myers Squibb BMY Stock Holding History

Alpha Paradigm Partners’s Portfolio BMY Stock Details BMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,198
Closed -$85K – 487
2022
Q3 		$85K Buy
+1,198
New +$86.9K 0.04% 378

Other funds holding BMY

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return

Alpha Paradigm Partners's BMY Position: Q4 2022 in Review

Alpha Paradigm Partners sold out of Bristol-Myers Squibb (BMY) in Q4 2022, closing a stake of 1,198 shares — an estimated $85K sold.

Alpha Paradigm Partners first reported a position in BMY in Q3 2022 and held it in 1 quarter. The position peaked at $85K in Q3 2022. 2,600 funds tracked by Wall St. Rank hold BMY as of Q4 2022.

  • Alpha Paradigm Partners reported no remaining Bristol-Myers Squibb position as of Q4 2022 after selling out during the quarter.
  • Alpha Paradigm Partners sold 1,198 Bristol-Myers Squibb shares in Q4 2022, an estimated $85K.
  • Alpha Paradigm Partners first reported a position in Bristol-Myers Squibb in Q3 2022 and held it in 1 quarter.
  • Alpha Paradigm Partners's Bristol-Myers Squibb position peaked at $85K in Q3 2022.
  • 2,600 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2022.

Based on Alpha Paradigm Partners's 13F filing for Q4 2022, filed 13 Feb 2023.